CVR Medical Corp. Announces Completion of Preliminary Review of the Restructuring-Agreement
Vancouver, British Columbia--(Newsfile Corp. - December 15, 2020) - CVR Medical Corp. (TSXV: CVM) (OTC: CRRVF) ("CVR Medical" or the "Company" or "we") a Canadian listed and US based healthcare company in the medical device market is pleased to announce the proposed restructuring agreement between CVR Medical Corp. and CVR Global Inc. (the "Proposed Restructuring") has been preliminarily reviewed by the TSX Venture Exchange (the "Exchange"). The Exchange's final acceptance of the Proposed Restructuring is conditional upon the Company satisfying the filing requirements (the "Requirements") as outlined in Policy 5.3, Section 5.7 of the Exchange Corporate Finance Manual. The Requirements include, but are not limited to, the scheduling of an annual general and special meeting of shareholders (the "Annual General and Special Meeting"). In order to approve, confirm and ratify the Proposed Restructuring, a majority of the minority shareholders must approve the Proposed Restructuring at the Annual General and Special Meeting, as set out in Multilateral Instrument 61-101- "Protection of Minority Security Holders in Special Transactions".
CVR Medical Corp. President and Interim CEO, Paul Blunden, M.D., reports, "the Company is pleased to have cleared this procedural hurdle and look forward to satisfying the remaining TSX-V and securities law requirements to finalize the Proposed Restructuring".
About CVR Medical
CVR Medical Corp. is a healthcare company that operates in the medical device industry focused on the commercialization of its disruptive, proprietary Carotid Stenotic Scan device ("CSS"). The CSS is a diagnostic tool that encompasses subsonic, infrasonic, and low frequency sound wave analysis technology. The CSS is a patented device designed to detect and measure carotid arterial stenosis. CVR Medical's shares are listed on the OTCQX under the symbol "CRRVF". The Company is listed for trading under the symbol "CVM". Additional information regarding the Company can be found in our recent filings with the SEDAR as well as the information maintained on our website at www.cvrmed.com
ON BEHALF OF THE BOARD:
(signed) Paul Blunden, M.D.
President & Director, interim CEO and CFO
For further information contact:
Paul Blunden, M.D., President/ Director, interim CEO and CFO
This press release contains forward-looking information that involves various risks and uncertainties regarding future events related to: trading on and dialogue with the Exchange, communications and negotiations with CVR Global, dialogue with certain advisors, the Proposed Restructuring, the License Agreement, the Review, certain corporate and securities law requirements, raising capital and potential litigation. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements and are not guarantees of future performance of the Company. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management's current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, including: (1) a failure or material setback in the Company satisfying the remaining conditions outlined by the TSX-V; (2) a failure of the Company to raise capital sufficient capital to relaunch the Company; (3) an inability to complete the Proposed Restructuring with CVR Global: (4)a downturn in general economic conditions in North America and internationally; (5)the inherent uncertainties and speculative nature associated with commercialization of technology and the practice of medicine; (6) a change in health regulations; (7) any number of events or causes which may delay or cease commercialization and development of the CSS Device; (8) the risk that the Company does not execute its business plan; (9) the risk of litigation between the Company and certain shareholders and the risk of litigation generally; (10) an inability to retain key employees; (11) an inability to finance operations and growth; (12) compliance with certain corporate and securities law requirements; and (13) other factors that are beyond the Company's control. These forward-looking statements are made as of the date of this news release and, except as required by law, the Company assumes no obligation to update these forward-looking statements, or to update the reasons why actual results differed from those projected in the forward-looking statements.
THE TSX VENTURE EXCHANGE INC. HAS NEITHER APPROVED NOR DISAPPROVED THE CONTENTS OF THIS PRESS RELEASE. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/70313